Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity,
cellular kinetics, immunogenicity, and exploratory biomarkers.